Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334:1181 (9 June), doi:10.1136/bmj.39237.658171.DB
Jeanne Lenzer
Boston
| The first 150 words of the full text of this article appear below. |
Officials in Nigeria have filed criminal and civil charges against Pfizer for its role in the deaths and disabilities of children who were treated with an experimental drug during a meningitis outbreak in Kano in 1996.
The charges, filed by government prosecutors in Nigeria, follow three attempts by families of the children to sue in US courts. All three attempts were denied after Pfizer successfully argued that the US courts were not an appropriate forum.
Four separate legal actions have been filed in Nigeria, including 31 criminal counts against 10 people, according to the Washington Post (www.washingtonpost.com, 2 Jun, "Pfizer faces new charges over Nigerian drug test"). The plaintiffs also seek a total of $9bn (£4.5bn;
7bn) in civil suits.
The charges stem from Pfizer's test of its unlicensed drug, trovafloxacin (Trovan) to treat 100 children with meningitis. A comparator group of 100 children were treated with a
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Read all Rapid Responses